완화의료병동 암환자들의 섬망 치료를 위해 사용된 항정신병 약물의 효과 및 안전성 비교
Efficacy and Safety of Antipsychotics for Delirium Treatment in Cancer Patients Receiving Palliative Care
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Delirium is a neuropsychiatric disorder characterized by sudden impairments in consciousness, attention, and perception. The evidence of successful pharmacological interventions for delirium is limited, and medication recommendations for managing delirium are not standardized. This study aimed to provide evidence of antipsychotics for symptomatic treatment of delirium in cancer patients receiving palliative care. Methods: We retrospectively reviewed adult cancer patients in palliative care who received antipsychotic delirium treatment at Severance Hospital between January 2016 and June 2019. The efficacy was evaluated primarily by resolution rates. The resolution of delirium was defined as neurological changes from drowsiness, confusion, stupor, sedation, or agitation to alertness or significant symptomatic improvements described in the medical records. The safety was studied primarily by adverse drug reaction incidence ratios. Results: Of the 63 enrolled patients, 60 patients were included in the statistical analysis and were divided into three groups based on which antipsychotic medication they were prescribed [quetiapine (n=27), haloperidol (n=25) and co-administration of quetiapine and haloperidol (n=8)]. The resolution ratio showed quetiapine to be more effective than haloperidol (p=0.001). No significant differences were seen in adverse drug reaction rates among the three groups (p=0.332). Conclusions: Quetiapine was considered the most effective medication for delirium, with no significant differences in adverse drug reaction rates. Therefore, quetiapine may be considered a first-line medication for treating delirium in cancer patients receiving palliative care. However, further studies comparing more diverse antipsychotics among larger populations are still needed.
Abstract
Background: Delirium is a neuropsychiatric disorder characterized by sudden impairments in consciousness, attention, and perception. The evidence of successful pharmacological interventions for delirium is limited, and medication recommendations for managing delirium are not standardized. This study aimed to provide evidence of antipsychotics for symptomatic treatment of delirium in cancer patients receiving palliative care. Methods: We retrospectively reviewed adult cancer patients in palliative care who received antipsychotic delirium treatment at Severance Hospital between January 2016 and June 2019. The efficacy was evaluated primarily by resolution rates. The resolution of delirium was defined as neurological changes from drowsiness, confusion, stupor, sedation, or agitation to alertness or significant symptomatic improvements described in the medical records. The safety was studied primarily by adverse drug reaction incidence ratios. Results: Of the 63 enrolled patients, 60 patients were included in the statistical analysis and were divided into three groups based on which antipsychotic medication they were prescribed [quetiapine (n=27), haloperidol (n=25) and co-administration of quetiapine and haloperidol (n=8)]. The resolution ratio showed quetiapine to be more effective than haloperidol (p=0.001). No significant differences were seen in adverse drug reaction rates among the three groups (p=0.332). Conclusions: Quetiapine was considered the most effective medication for delirium, with no significant differences in adverse drug reaction rates. Therefore, quetiapine may be considered a first-line medication for treating delirium in cancer patients receiving palliative care. However, further studies comparing more diverse antipsychotics among larger populations are still needed.
참고문헌 (30)
- Grover S, "Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium", J Psychosom Res, 71(4), pp.277~281 (2011)
- Yoon HJ, "Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium", BMC Psychiatry, 13, pp.240~ (2013)
- Breitbart W, "An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients", Psychosomatics, 43(3), pp.175~182 (2002)
- Bush SH, "Delirium in adult cancer patients : ESMO Clinical Practice Guidelines", Ann Oncol, 29(Suppl 4), pp.iv143~iv165 (2018)
- Lawlor PG, "Occurrence, causes, and outcome of delirium in patients with advanced cancer : a prospective study", Arch Intern Med, 160(6), pp.786~794 (2000)
- Thomason JW, "Intensive care unit delirium is an independent predictor of longer hospital stay : a prospective analysis of 261 non-ventilated patients", Crit Care, 9(4), pp.R375~81 (2005)
- Agar MR, "Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial", JAMA Intern Med, 177(1), pp.34~42 (2017)
- "Palliative Care"[URL]
- Gaertner J, "Benzodiazepines and", or neuroleptics for the treatment of delirium in palliative care?-a critical appraisal of recent randomized controlled trials, 2019, pp.8(4), 504~515
- Sundararajan V, "New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality", J Clin Epidemiol, 57(12), pp.1288~1294 (2004)
- "Opioid calculator"[URL]
- Lawlor PG, "Delirium in patients with cancer: assessment, impact, mechanisms and management", Nat Rev Clin Oncol, 12(2), pp.77~92 (2015)
- Maldonado JR, "Neuropathogenesis of delirium : review of current etiologic theories and common pathways", Am J Geriatr Psychiatry, 21(12), pp.1190~1222 (2013)
- 서민석, "섬망의 돌봄: 완화의료 영역에서의 진단, 평가 및 치료", Journal of Hospice and Palliative Care, 19(3), pp.201~210 (2016), 한국호스피스완화의료학회[DOI]
- Bush SH, "Clinical assessment and management of delirium in the palliative care setting", Drugs, 77(15), pp.1623~1643 (2017)
- Pornjira Pariwatcharakul, "Antipsychotic Prescribing Pattern for Geriatric Patients with Delirium in Thailand", Clinical Psychopharmacology and Neuroscience, 8(3), pp.144~148 (2010), 대한정신약물학회
- Hui D, "Effect of lorazepam with haloperidol vs haloperidol alone on agitated delirium in patients with advanced cancer receiving palliative care : a randomized clinical trial", JAMA, 318(11), pp.1047~1056 (2017)
- Grover S, "Comparative effectiveness of quetiapine and haloperidol in delirium : A single blind randomized controlled study", World J Psychiatry, 6(3), pp.365~371 (2016)
- "Micromedex® (electronic version). IBM watson Health. Alprazolam. Adverse Effects"[URL]
- Verbalis JG, "Brain volume regulation in response to changes in osmolality", Neuroscience, 168(4), pp.862~870 (2010)
- Adrogué HJ, "Hyponatremia", N Engl J Med, 342(21), pp.1581~1589 (2000)
- Zieschang T, "The association of hyponatremia, risk of confusional state, and mortality", Dtsch Arztebl Int, 113(50), pp.855~862 (2016)
- 이유진, "섬망 환자에서 Quetiapine과 Haloperidol의 치료 효과 비교 : 전향적, 무작위 연구", 생물정신의학, 16(1), pp.15~24 (2009), 대한생물정신의학회
- Maneeton B, "Quetiapine versus haloperidol in the treatment of delirium : a doubleblind, randomized, controlled trial", Drug Des Devel Ther, 7, pp.657~667 (2013)
- 최학규, "섬망의 치료에 대한 Quetiapine과 Haloperidol의 전향적 개방형 연구", 정신신체의학, 13(2), pp.85~94 (2005), 한국정신신체의학회
- Ryan K, "Validation of the confusion assessment method in the palliative care setting", Palliat Med, 23(1), pp.40~45 (2009)
- Weaver CB, "A retrospective analysis of the effectiveness of antipsychotics in the treatment of ICU delirium", J Crit Care, 41, pp.234~239 (2017)
- Boettger S, "Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium : A comparison of efficacy, safety, and side effects", Palliat Support Care, 13(4), pp.1079~1085 (2015)
- Hale GM, "An evaluation of adverse drug reactions associated with antipsychotic use for the treatment of delirium in the intensive care unit", J Pharm Pract, 29(4), pp.355~360 (2016)
- Faul F, "G* Power 3 : A flexible statistical power analysis program for the social, behavioral, and biomedical sciences", Behav Res Methods, 39(2), pp.175~191 (2007)